ANALYST-UPGRADE filed Aug 20, 2026 at 06:05 ET
Morgan Stanley upgraded Merck & Co., Inc. (MRK) from Equal-Weight to Overweight on August 20, 2026, with a new price target of $179, a massive 54.3% increase from its prior $116 target. The upgrade is part of a two-firm cluster on MRK, with RBC Capital simultaneously downgrading to Sector Perform (PT $150). Morgan Stanley's call is contrarian to the consensus mean target of $137.73 and median of $142, but aligns with the bullish tilt in consensus (69% Buy/Strong Buy). The firm's 55% accuracy on 4,986 calls is below average among covering firms, and its 43% accuracy on 7 MRK calls is also below average. The stock trades at $152.20, already above the consensus mean and median, implying 17.6% upside to Morgan Stanley's new target. Momentum is mixed: 2 upgrades and 1 downgrade in 30 days, with EPS revisions slightly negative for the current quarter (1 up, 5 down in 30 days). Insider selling is heavy, with five sales totaling ~$14.3M in August, including a $10.7M sale by EVP Zachary Jennifer, which diverges from the bullish analyst signal. The bottom line: Morgan Stanley's bold PT hike is a standout, but the firm's below-average track record on MRK and heavy insider selling warrant caution.